Human papillomavirus 52 (HPV52) is a high-risk type within the Alphapapillomavirus genus. It has a circular double-stranded DNA genome packaged in a non-enveloped capsid and infects mucosal epithelium of the anogenital tract. Persistent HPV52 infection can lead to oncogenesis, although it is less common than infections with HPV16 or HPV18.
Virology & Oncogenic Mechanisms
HPV52 is classified among the high risk papillomavirus types identified by oncologic agencies. It belongs to the alpha 9 species group along with types 16, 31, 33 and 58. The viral genome encodes early proteins E1–E7 and structural proteins L1–L2. E6 and E7 oncoproteins bind and degrade p53 and retinoblastoma proteins, driving cell cycle progression and inhibiting apoptosis. After entry via heparan sulfate proteoglycans, the virus establishes its genome as a circular episome in basal keratinocytes and replicates synchronously with cell differentiation. Integration of HPV52 DNA into the host genome results in constitutive E6/E7 expression and is associated with malignant transformation. While HPV16 and HPV18 account for most HPV related cancers, other high‑risk types including 31, 33, 45, 52 and 58 together contribute to about 15 % of cervical cancers.
Clinical Impact and Prevention
Persistent HPV52 infection is associated with high grade cervical intraepithelial neoplasia and invasive cervical carcinoma, especially in Asian populations where its prevalence is higher. It may also be implicated in cancers of the vagina, vulva, anus and penis, though these associations are less well defined. Most infections are transient and cleared by the host immune response within a couple of years. The nonavalent (9‑valent) vaccine includes HPV52 along with types 6, 11, 16, 18, 31, 33, 45 and 58, providing direct protection against this type. Regular cervical screening using Pap tests and high‑risk HPV DNA assays enables early detection of HPV52‑related lesions. Safe sexual practices and vaccination before the onset of sexual activity remain the most effective preventative measures. HPV52 is a high‑risk HPV type whose persistent infection can lead to cervical and other anogenital cancers. Inclusion of HPV52 in the nonavalent vaccine and continued screening help reduce the disease burden associated with this virus. Related Terms: HPV16, HPV18, HPV58, Nonavalent vaccine, Cervical intraepithelial neoplasia